Exploring the relationship between DNA methylation age measures and psychoneurological symptoms in women with early-stage breast cancer.

Autor: Yang GS; University of Connecticut School of Nursing, Storrs, CT, USA., Yang K; Medical College of Wisconsin Department of Institute for Health and Equity Division of Biostatistics, Milwaukee, WI, USA., Weaver MT; University of Florida College of Nursing, Gainesville, FL, USA., Lynch Kelly D; University of Florida College of Nursing, Gainesville, FL, USA., Dorsey SG; School of Nursing Department of Pain and Translational Symptom Science, University of Maryland, Baltimore, MD, USA., Jackson-Cook CK; Department of Pathology & Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA., Lyon DE; University of Florida College of Nursing, Gainesville, FL, USA. delyon@ufl.edu.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Dec 20; Vol. 31 (1), pp. 65. Date of Electronic Publication: 2022 Dec 20.
DOI: 10.1007/s00520-022-07519-z
Abstrakt: Purpose: The epigenetic clock has been acknowledged as an indicator for molecular aging, but few studies have examined possible associations of DNA methylation (DNAm) age or age acceleration (AA) with symptom burden in individuals who are treated for cancer. This study explored the association of DNAm age or AA with psychoneurological (PN) symptoms, including cognitive impairment, fatigue, sleep disturbances, pain, and depressive symptoms, in breast cancer survivors over a 2-year period.
Methods: We measured PN symptoms using reliable instruments and DNAm levels by Infinium HumanMethylation450K BeadChip (N = 72). DNAm age was calculated by the Horvath, Grim, and Hannum-based intrinsic and extrinsic age estimations. AA was defined by the residual regressing estimated epigenetic age on chronological age. Mixed regression models were fitted for AA and changes in AA to study the association over time. Separate linear regression models and a mixed-effects model were fitted for AA at each time point.
Results: Horvath-AA, Grim-AA, and extrinsic epigenetic AA were significantly changed over time, while intrinsic epigenetic AA did not exhibit any temporal changes. Increased AA was associated with greater anxiety and fatigue, as well as worse cognitive memory, adjusting for race, BMI, income, chemotherapy, radiation therapy, and chronological age. Increased DNAm age was associated with greater anxiety over 2 years.
Conclusion: Our findings suggest DNAm age and AA may be associated with PN symptoms over the course of cancer treatment and survivorship. Some PN symptoms may be amenable to preventive interventions targeted to epigenetic clocks that influence aging-associated processes.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: